View source for MK-2048

== MK-2048 ==

'''MK-2048''' (pronunciation: em-kay-two-zero-four-eight) is a second-generation [[integrase inhibitor]] used in the treatment of [[HIV]] infections. It is a derivative of [[raltegravir]], the first approved integrase inhibitor, and has shown to be effective against HIV strains resistant to raltegravir.

=== Etymology ===

The name "MK-2048" is a product code assigned by the pharmaceutical company [[Merck & Co.]], with "MK" standing for Merck and "2048" being a sequential number in their drug development program.

=== Mechanism of Action ===

MK-2048 inhibits the [[integrase]] enzyme, which is essential for the replication of HIV. By blocking this enzyme, MK-2048 prevents the virus from integrating its genetic material into the host cell, thereby stopping the replication process.

=== Related Terms ===

* [[Integrase Inhibitors]]: A class of antiretroviral drugs that block the integrase enzyme, preventing HIV from integrating its genetic material into the host cell.
* [[Raltegravir]]: The first approved integrase inhibitor, from which MK-2048 is derived.
* [[HIV]]: Human Immunodeficiency Virus, the virus that causes AIDS. MK-2048 is used in the treatment of HIV infections.
* [[Merck & Co.]]: The pharmaceutical company that developed MK-2048.

[[Category:Pharmaceuticals]]
[[Category:HIV]]
[[Category:Antiretroviral drugs]]

{{dictionary-stub}}